Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

Pluristem Therapeutics, Inc. (PSTI)

(Delayed Data from NSDQ)

$0.65 USD

+0.01 (1.27%)

Updated May 3, 2019 04:13 PM ET

After-Market: $0.65 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Pluri Inc. [PSTI]

Reports for Purchase

Showing records 1 - 20 ( 82 total )

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

07/15/2022

Pages: 4

Encouraging Initial Data from HIPGEN Study; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

07/13/2022

Pages: 5

Lowering to Neutral from BUY as Pluristem Hip Trial Misses the Primary Endpoint

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

05/10/2022

Pages: 5

BUY: Reports 3Q22 - $61M in Cash & Equivalents

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

02/24/2022

Pages: 6

BUY: The Deal is On - Food Company Tnuva is In for a Bite

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

01/10/2022

Pages: 6

BUY: Food Company Tnuva Invests $7.5M for R&D Service

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

12/01/2021

Pages: 6

BUY: Swinging Hips - PLX-PAD Pivotal Trial Fully Enrolled-

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

12/01/2021

Pages: 6

BUY: Swinging Hips - PLX-PAD Pivotal Trial Fully Enrolled

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

09/28/2021

Pages: 10

ValuEngine Detailed Valuation Report for PSTI

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

07/08/2021

Pages: 5

Is There a Signal in ARDS? Pluristem will Analyze the Current Data Sets

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

05/10/2021

Pages: 7

PLX-R18 Shows Potential in Hematological Indication; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

05/04/2021

Pages: 5

BUY: Phase 1 Study Shows Promise in HCT

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

02/16/2021

Pages: 7

Catalyst-Rich 2021 Expected; Higher $10 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

12/10/2020

Pages: 6

Opportunities Beyond CLI Remain Intact; Lower PT to $9; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

12/09/2020

Pages: 7

BUY: CLI Study is Halted as Low Event Rate in Control Diminutive to the Study?s Power

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

12/07/2020

Pages: 7

Positive PLX-R18 Data at ASH; CLI Phase 3 Interim Data Imminent; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

10/07/2020

Pages: 5

BUY: China Virus Trial Expands to Israel

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

09/15/2020

Pages: 5

BUY: A Pivotal Year

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

08/27/2020

Pages: 5

BUY- COVID-19 - ARDS Expanded Access Granted

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

08/10/2020

Pages: 7

BUY: COVID-19 - ARDS Trial Expands to Europe

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

06/11/2020

Pages: 7

BUY: The U.S. Phase 2 Trial in COVID-19 ? ARDS Begins

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

previous
1
2
3
4
5
next

// eof